Yahoo•2026-04-21
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market ValidationHAE — Haemonetics Corp
NYSE · Health Care · Health Care
$60.21-27.88%Market cap2.64B
- Latest Close
- $60.21
- 30-Day Move
- -27.9%
- Market Cap
- $2.6B
- Shares Outstanding
- 46,470,000
- P/E Ratio
- 15.05
- P/B Ratio
- 3.89
Analyst consensus: Buy · 15 analysts
NYSE:HAEHealth Care / Health CareDelayed public snapshot
Haemonetics Corp
A read-only Alphactor snapshot forHaemonetics Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$60.21
30-Day Move
-27.9%
Market Cap
$2.6B
Shares Outstanding
46,470,000
P/E Ratio
15.05
P/B Ratio
3.89
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$60.21
-27.9%last 90 delayed daily bars
Market cap$2.6B
90D High
$86.11
90D Low
$53.88
Avg Volume
794,631
What stands out
Gross margin is running at 59.3%, which gives a quick read on operating quality before you open the full model.
Net margin is 13.3%, useful for comparing HAE against peers in Health Care.
HAE is down 27.9% over the last 30 trading days shown on this page.
Latest operating income is $68M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$59.56
Rule of 40
14.4%
Dark Pool Short %
21.4%
Fundamentals snapshot
Latest Close
$60.21
30-Day Move
-27.9%
Market Cap
$2.6B
Shares Outstanding
46,470,000
P/E Ratio
15.05
P/B Ratio
3.89
ROE
20.4%
ROA
6.8%
Gross Margin
59.3%
Operating Margin
19.1%
Net Margin
13.3%
Debt / Equity
1.49
Current Ratio
1.62
Latest Revenue
$339M
Financial statement snapshot
Revenue
$339M
Gross Profit
$202M
Operating Income
$68M
Net Income
$45M
Gross Margin
5932.0%
Net Margin
1331.0%
Current Ratio
1.62
Debt / Equity
1.49
Valuation snapshot
Fair Value
$59.56
Upside / Downside
-1.1%
Signal
Fairly Valued
Implied Growth
10.1%
DCF
$41.94
EPV
$10.09
EV/Rev
$126.66
Growth Assumption
11.1%
Discount Rate
9.4%
Terminal Growth
2.0%
Base FCF
$142M
Valuation spread
Current Price
$60.21
Composite Fair Value
$59.56
DCF
$41.94
EPV
$10.09
EV/Rev
$126.66
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Quality snapshot
Altman Z
2.17
Grey
Piotroski
6
Moderate (4-6)
Cash Conversion
1.08x
Rule of 40
14.4%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $993M | $71M | $43M | $76M |
| 2023-12-31 | $1.2B | $156M | $115M | $82M |
| 2024-12-31 | $1.3B | $173M | $118M | $144M |
| 2025-12-31 | $1.4B | $201M | $168M | $142M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Yahoo•2026-04-17
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide ReviewAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$98,784
Sell Value
$0
Buys
1
Sells
0
Buy Value
$98,784
Sell Value
$0
Buy/Sell Ratio
1.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2025-11-10 | KROLL MARK W | Buy | 1,400 | $70.56 |
| 2025-10-31 | Galvin Roy | F | 145 | $50.01 |
| 2025-09-17 | Miller Laurie A. | F | 238 | $49.95 |
| 2025-07-24 | Johnson Lloyd Emerson | A | 2,693 | $0.00 |
| 2025-07-24 | Bryant Diane M | A | 2,693 | $0.00 |
| 2025-07-24 | Pomeroy Claire | A | 2,693 | $0.00 |
| 2025-07-24 | Dockendorff Charles J | A | 2,693 | $0.00 |
| 2025-07-24 | Zane Ellen M | A | 2,693 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 1,510,823 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,459,243 | 0.03% | 2025-12-31 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Berman Genesis Fund | 1,221,501 | 0.03% | 2026-03-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,173,213 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1,061,914 | 0.02% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 600,786 | 0.01% | 2025-12-31 |
| AQR Funds-AQR Long-Short Equity Fund | 547,270 | 0.01% | 2025-12-31 |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 544,170 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-08-14
--
--
Fisher Investments
Filed 2026-02-09
--
--
BlackRock
Filed 2024-05-10
$511M
--
Vanguard Group
Filed 2026-01-29
$382M
-1.5%
Goldman Sachs
Filed 2026-02-10
$108M
+132.0%
FMR LLC (Fidelity)
Filed 2026-02-17
$106M
+9.1%
Citadel Advisors
Filed 2026-02-17
$103M
--
Capital Research Global Investors
Filed 2025-05-12
$100M
--
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
3.93
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
15
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.